You are here: 

Pierre B. Lafrenière

Pierre Lafreniere

Pierre B. Lafrenière is the Executive Vice-President of FTM Synergis Capital,a firm specialized in mergers & acquisitions as well as corporate finance transactions. In addition to the CCS, he sits on the board of Fondaction as an independent member (where he is also a member of the executive committee) and chairs the audit committee of the Quebec Bar. He is also a part of different business advisory committees. Previously, he was Executive Vice-President, Major Accounts Financing and Mandates at Investissement Québec.

A member of the Quebec Bar and the Canadian Bar Association, Pierre B. Lafrenière holds a Law degree and an international MBA with a specialization in financial services and insurance awarded jointly by three renowned universities, namely Vlerick Leuven Gent Management School in Belgium, Université de Saint-Gallen in Switzerland and HEC Montréal. He has the designation of administrateur de société certifié from the Collège des administrateurs de société and is also recognized as a Chartered Director.

In the course of his career, Mr. Lafrenière has taught at one of the École du Barreau du Québec’s professional training centres and lectured at the Association des économistes québécois (ASDEQ) as well as the Canadian Bar Association. He is also a chartered arbitrator certified by the Centre d’arbitrage national et international du Québec

Mr. Lafrenière is recognized, among other things, for his ability to mobilize diverse parties to achieve efficiency in operations. He also possesses a solid experience in matters of governance

“My involvement with the Canadian Cancer Society is important to me and I would like to share my experience with the organization by supporting its board of directors in strategic decisions designed to do more in the fight against cancer and ultimately eradicate this terrible disease called cancer.”



Dr Jessie Lee-McIsaac Preventing cancer through healthy living school policies

Read more

Together we can reduce the burden of cancer

Icon - beaker

Last year, we only had the resources available to fund 40% of high-priority research projects. Imagine the impact we could have if we were able to fund 100%.

Learn more